Completed PHASE2 INTERVENTIONAL NCT00189722

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Sponsor: Astellas Pharma Europe B.V.

Conditions Asthma, Bronchial Bronchial Asthma

Interventions Tacrolimus

Updated 8 times since 2017 Last updated: Apr 15, 2008 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00189722, this PHASE2 trial focuses on Asthma, Bronchial and Bronchial Asthma and remains completed. Sponsored by Astellas Pharma Europe B.V., it has been updated 8 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Feb 2026 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Europe B.V.
Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bialystok, Poland , Brno, Czechia , Deggendort, Germany , Dnipro, Ukraine , Hamburg, Germany , Hanover, Germany , Kiev, Ukraine , Krakow, Poland , Krhanice, Czechia and 14 more locations